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Each mature T cell or B cell has an allele with a 
productively rearranged T cell receptor (TCR) or B cell 
receptor (BCR) gene, respectively. The repertoire of TCRs 
and BCRs in the blood of a healthy person is diverse, with 
no single specific rearrangement found in more than one 
percent of cells, and most rearrangements representing a 
minute fraction of total B cells or T cells[1-3]. When a 
leukemia or lymphoma develops, one or a small number 
of  specific  clones  proliferate  rapidly.  The  cancerous 
clone (or clones) is “tagged” by the unique TCR or BCR 
sequences from the original cell. In leukemia patients, a 
single clone often accounts for over half of all B cells or 
T cells in the blood. The clonality of an adaptive immune 
receptors in the blood is often utilized in the diagnosis 
of lymphoma or leukemia. One of the two commonly 
utilized methods to track minimal residual disease (MRD) 
after treatment is to design a set of allele specific PCR 
primers that bind to the rearranged receptor in a specific 
cancerous clone[4].
High-throughput sequencing has the potential to 
significantly  improve  sensitivity  and  reduce  cost  for 
clonal detection and post-treatment monitoring of B and 
T cell leukemias and lymphomas. For leukemia, direct 
sequencing of BCR and TCR genes from blood cells is 
straightforward. However, in the case of lymphoma, 
the primary tumor resides in the lymph node, with the 
fraction of cancerous cells found in blood variable. A 
recent paper by He et al. presents the interesting idea that 
free DNA in blood plasma is potentially a better source 
of lymphoma specific DNA than white blood cells[5]. In 
the case of non-Hodgkins lymphoma (NHL), they show 
that the tumor specific BCR sequences can be detected 
in plasma. In addition, for an NHL cohort with plasma 
samples, but no corresponding tumor samples, they are 
able to identify a dominant rearranged BCR sequence 
in approximately half the patients, which is likely to be 
tumor derived DNA. 
He et al. employ a targeted capture and sequencing 
approach that they call IgCap. It is similar to a shotgun 
sequencing approach, yet they include an enrichment step 
between fragmentation and sequencing which enriches for 
sequences derived from the IgH locus. Fragmented DNA 
sequences from plasma have adapters attached to each 
end, and are then hybridized to a set of probes that bind 
to the germline encoded fragments of the IgH locus. The 
subset of plasma DNA fragments which hybridize to the 
IgH derived probes are then sequenced using Illumina’s 
high-throughput sequencing technology. 
This methodology has some pros and cons. On 
the positive side, the method is capable of detecting the 
majority of sequences in the IgH locus, including any 
possible non-templated rearrangement. Importantly, IgCap 
was effectively able to detect and identify lymphoma 
specific IgH sequences in plasma. There are also a few 
negative aspects of this technology. First, the hybridization 
step does not distinguish between rearranged and non-
rearranged IgH sequences. So, an unknown portion of the 
DNA fragments sequenced will truly be derived from the 
rearranged IgH loci. Second, fragmenting sequences and 
then reconstructing the pieces requires sequencing each 
receptor multiple times. For a diverse, non-templated 
region of DNA, such as the rearranged IgH locus, to 
detect an specific IgH sequence, many copies would need 
to be in the plasma and sequenced.
Direct methods for sequencing rearranged BCR and 
TCR genes have been developed over the past few years[2, 
3, 6, 7]. These methods use primers specific to each pair 
of V and J segments and attempt to directly amplify and 
sequence all possible rearrangements. These methods 
avoid the cons of IgCap, but they have not been tested 
with plasma DNA. The IgCap method could be compared 
with the direct sequencing methods to determine which 
has greater sensitivity and also lower costs. 
The work of He et al. is an important step in 
showing that high-throughput sequencing of the adaptive 
immune receptor repertoire has direct clinical application. 
The idea of focusing on plasma DNA instead of cells Oncotarget 2011; 2:  287 - 288 288 www.impactjournals.com/oncotarget
for monitoring lymphoma is intriguing. Hopefully, the 
larger scale experiments required to prove utility will be 
accomplished soon and these or similar methods will be 
moved into the clinic. 
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